WHO WE ARE

The TNA Therapeutics team has been working together since 2015 with the collective passion to develop novel therapies for cancer patients with an unmet need to provide long-term survival benefit.

TNA TEAM

Drug Development experts that see opportunities to advance medicines in difficult to treat cancers

TnA therapeutics is an independent company with a strong focus on Cancer Stem Cell therapies. We are developing a pipeline of first-in-class novel agents that target the CSC population with the potential to provide long-term survival benefit for patients.

SCIENTIFIC ADVISORY COMMITEE

Experts in BCL3, CRC and TNBC

Prof. Andrea Brancale

Molecular Modeling

Over 30 years experience in Molecular Modelling with >280 publications. Prof. Andrea Brancale is one of the scientific inventors on the Bcl3 inhibitor programme. Current roles; Chair Medicinal Chemistry at University of Chemistry and Technology (Prague), Member Board Of Directors, International Society for Antiviral Research, Co-Founder and Director at Ceridwen Oncology Ltd, Scientific Director at Life Sciences Research Network Wales. Previous roles; Professor of Medicinal Chemistry at Cardiff University, Scientific Director of the Life Science Research Network Wales

Prof. Richard Clarkson

Cancer Biologist

Over 30 years experience in cancer and cell biology research with >70 publications in cancer biology. Prof. Richard Clarkson is one of the scientific inventors on the Bcl3 inhibitor programme. Current roles; Director of European Cancer Stem Cell Research Institute

Prof. Andrew Westwell

Medicinal Chemist

Over 25 years academic career in cancer drug discovery with >230 publications focused on translational drug discovery. Prof. Andrew Westwell is one of the scientific inventors on the Bcl3 inhibitor programme. Current roles; Prof. of Medicinal Chemistry at Cardiff University School of Pharmacy & Pharmaceutical Sciences. Board member, Velindre University NHS Trust, home to the Velindre Cancer Centre. Previous roles; Dean of Research & Innovation, College of Biomedical and Life Sciences, CU.

Dr. Amy Krie M.D

Breast Cancer Specialist

Over 20 years practicing breast medical oncology. Active in industry sponsored & cooperative group clinical trials from early phase to phase 3 studies. Current roles; Medical Oncologist at Allina Health Cancer Institute. Consultant & speaker at Novartis, Daiichi Sankyo & AstraZeneca. Previous roles; Served on NSABP Foundation & NRG breast cancer committees, Director of breast medical oncology at Piper Breast Centers, Clinical director of breast medical oncology at Avera Health, Dr Krie was instrumental in establishing robust clinical trials program in addiction to cutting edge research in genomic guided treatment of breast cancer.

Dr. Robert Evans

Clinical Development

Over 22 years of global experience in the pharmaceutical industry, in senior research, development & strategy roles. Successfully led product development in a wide range of therapeutic areas, bringing innovative medicines to patients. Previous roles; VP of Clinical Development at Tiziana Life Sciences, Head of Clinical Development at Glenmark Pharmaceuticals with accountability for a portfolio of new chemical entities in oncology and immunology, leading clinical development teams for rheumatology, dermatology, respiratory and rare diseases at Regeneron Pharmaceuticals.

Prof. Richard Wilson M.D

Colorectal Cancer Specialist

Over 30 years experience in medical oncology with >100 publications. Works in experimental cancer medicine and in lower GI cancer and conducts translational and clinical research, particularly related to developmental therapeutics and colorectal cancer. Has been Chief Investigator on many local, national and international cancer clinical trials in both early and late phase settings. Current role: Professor in Gastrointestinal Oncology at the School of Cancer Sciences in the University of Glasgow and Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre. Previous roles: Clinical Director of the N. Ireland Cancer Trials Network and Clinical lead, Belfast Experimental Cancer Medicine Centre. Prof. Set up the first early phase cancer clinical trials programme in Ireland.

Prof. Rob Jones M.D PhD

Medical Oncologist

Over 25 years experience in both Medicine and Science with >90 publications in scientific and clinical cancer research journals. Principal Investigator >35 Early Phase Trials Chief Investigator of 2 Investigator Led National Portfolio trials, FAKTION and FURVA. Current roles; Specialty Lead for Cancer in Wales, Early Phase Cancer Trials Lead, and Clinical Director of Research at Velindre Cancer Centre. Prof. Jones set up Wales's only Cancer Phase 1 Trials Unit & opened its 1st ever First in Human Trial, leading Global recruitment on it.

Prof. Bill Jusko M.D

Clinical Pharmacologist

Over 25 years experience in clinical pharmacology with >650 publications, his research covers clinical, basic, & theoretical pharmacokinetics and pharmacodynamics of diverse drugs. Current roles; Fellow of several scientific societies Previous roles; Asst. Professor of Pharmacology at Boston University School of Medicine, Director of the Clinical Pharmacokinetics Laboratory & Asst. Professor at University of New York at Buffalo. Served on many editorial boards & NIH review panels. Awards; Oscar B Hunter Career Award in Therapeutics from ASCPT(2018), AAPS Distinguished Pharmaceutical Scientist Award (2020)

TNA LEADERSHIP TEAM

Experienced team in oncology drug development & commercialization

Chief Executive Officer

James Tripp

Over 25 years pharmaceutical industry experience and has previously held c-suite level positions in successful biotech companies. Gaining valuable experience in some of the top global pharmaceutical companies(Bayer, Roche, Novo Nordisk and Regeneron). His commercial experience, network and overarching leadership will ensure successful, well- managed progression of TNA Therapeutics.

Chief Scientific Officer

Dr. Luke Piggott, Ph.D

Over 12 years of oncology experience, 8 years of drug development working with targeted therapies including virotherapies, small molecule inhibitors, antibodies and antibody-drug conjugates at all stages of development (early discovery through to Phase 3 and outlicensing). The lead TNAT-101's non-clinical pharmacology work to date. PhD in molecular biology and an expert in cancer stem cell targeting.

Chief Legal Officer

Thomas Knapp

Over 40 years of legal experience serving in senior positions within the pharmaceutical industry including chief legal officer and corporate secretary of Sucampo Pharmaceuticals, general counsel and corporate secretary at Galena Biopharma and Osiris Therapeutics. Previously appointed as the assistant attorney general of State of Illinois, Chicago and also served in various legal positions, including assistant general counsel of The Boeing Company.

Chief of Staff

Lois Marianne

Over 8 years experience managing businesses and professionals across a diverse range of sectors. Qualified AGILE project manager that has worked in the life sciences sector for the past 4 years, successfully managing national implementation programs within the NHS and in collaboration with charities and industry partners.

Chief Medical Officer

Dr. John Lee, M.D

Over 20 years' experience in cancer treatment and drug development. Prior CMO for Immunitybio where he initiated over 25 IND's in 4 years. Developed Anktiva from phase 1 to breakthrough designation and BLA submission. Oversaw pre-clinical development for all early-stage compounds-25 in total. Managed over 144 sites for clinical operations of 44 clinical trials.

Chief Financial Officer

Saleem Elmasri

Over 15 years experience in financial and management consulting. CPA and seasoned business professional in life sciences and technology sectors, helping dozens of clients navigate transactions in the public markets, compliance with SEC requirements, preparation of financial statements, preparation of technical position papers, coordination of audits, integration of newly acquired businesses and divestitures.